417 related articles for article (PubMed ID: 31757494)
21. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
[TBL] [Abstract][Full Text] [Related]
23. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
24. 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.
Niedzwiecki M; Hunt A; Nguyen V; Mehta H; Creuzot-Garcher C; Gabrielle PH; Guillemin M; Fraser-Bell S; Arnold J; McAllister IL; Gillies M; Barthelmes D
Acta Ophthalmol; 2022 Jun; 100(4):e920-e927. PubMed ID: 34519167
[TBL] [Abstract][Full Text] [Related]
25. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
26. Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Wiryasaputra S; Nguyen V; Arnold JJ; Ferrier R; Hinchcliffe P; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2020 Sep; 48(7):946-955. PubMed ID: 32463528
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
28. The VEGF Treatment of AMD Switch Study (The vTAS Study).
Curry B; Bylsma G; Hewitt AW; Verma N
Asia Pac J Ophthalmol (Phila); 2017; 6(6):481-487. PubMed ID: 29204996
[TBL] [Abstract][Full Text] [Related]
29. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
Chan CK; Jain A; Sadda S; Varshney N
Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
[TBL] [Abstract][Full Text] [Related]
30. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.
Zarranz-Ventura J; Parrado-Carrillo A; Nguyen V; Sararols L; Garay-Aramburu G; Puzo M; Arruabarrena C; Figueras-Roca M; Gillies MC; Casaroli-Marano RP;
Clin Exp Ophthalmol; 2022 Apr; 50(3):312-324. PubMed ID: 35106882
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
32. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
33. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
34. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
35. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
36. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
[TBL] [Abstract][Full Text] [Related]
37. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
[TBL] [Abstract][Full Text] [Related]
38. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
[TBL] [Abstract][Full Text] [Related]
40. Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project.
Invernizzi A; Nguyen V; Teo K; Barthelmes D; Fung A; Vincent A; Gillies M
Am J Ophthalmol; 2019 Aug; 204():105-112. PubMed ID: 30862501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
